amino pyrimidine
Recently Published Documents


TOTAL DOCUMENTS

74
(FIVE YEARS 20)

H-INDEX

11
(FIVE YEARS 2)

2021 ◽  
Author(s):  
Alexander W. Weig ◽  
Samantha L. Barlock ◽  
Patrick M. O'Connor ◽  
Orry M. Marciano ◽  
Richard Smith ◽  
...  

Infections that stem from bacterial biofilms are difficult to eradicate.


Author(s):  
Rong-Ji Xie ◽  
Jun-Hua Liu ◽  
Qiu-Yi Zhang ◽  
Yi-Jie Yang ◽  
Li-Qun Song ◽  
...  

An aerobic copper-catalyzed oxidative domino cyclization of methyl azaarenes with 6-amino-pyrimidine-2,4-diones and pyrazol-5-amines has been developed, which enables access to dipyrazolo/dipyrimidine-fused pyridines. Cu(OTf)2 is used as a transition-metal catalyst. The...


2020 ◽  
Vol 29 ◽  
pp. 100513
Author(s):  
Rajasekhar Chekkara ◽  
Venkata Reddy Gorla ◽  
E. Susithra ◽  
Reddymasu Sireesha ◽  
Sobha Rani Tenkayala ◽  
...  

Author(s):  
Zh. V. Ignatovich

Methodological approaches to the synthesis of 2-arylpyrimidine amides with predicted antitumor activity using the design of chimeric molecules by combining pharmacophore fragments of known antitumor drugs are considered. The results of the synthesis of chimeric amides containing, along with the 2-amino-pyrimidine fragment, fragments of other nitrogen and oxygen-containing heterocycles (piperazine, morpholine, isoxazole, etc.), aromatic cycles (benzene, methylnitroaniline, phenylenediamine) and functional (methyl-, amino-, carboxy-, etc.) groups in different positions of the molecule, are presented.


2020 ◽  
Vol 16 (1) ◽  
pp. 52-62
Author(s):  
Shehnaz Fatima ◽  
Subhash M. Agarwal

Background: EGFR is a clinically approved drug target in cancer. The first generation tyrosine kinase inhibitors targeting L858R mutated EGFR are routinely used to treat non-small cell lung cancer (NSCLC). However, the presence of a secondary mutation (T790M) tenders these inhibitors ineffective and thus results in the relapse of the disease. Objective: New reversible inhibitors are required, which act against T790M/L858R (TMLR) double mutants and overcome resistance. Method: In the present study, various Fragment based QSAR (G-QSAR) models along with interaction terms have been studied for amino-pyrimidine derivatives having biological activity against TMLR mutant enzyme. Results: The G-QSAR models developed using partial least squares regression via stepwise forward- backward variable selection technique showed the best results. The model showed a high correlation coefficient (r² = 0.86), cross-validation coefficient (q² = 0.81) and predicted correlation (predicted r² = 0.62), which indicated that the model is robust and predictive. Based on the model, it was revealed that at R1 position increasing saturated carbon (number of –CH atom connected with 3 single bonds i.e. SsssCHcount) and retention index (chi3) is desired for the enhancement of bioactivity. Additionally, at the R2 position, increasing lipophilic character (slogp) and at site R3, the polarizability of compound need to be increased for better inhibitory activity. We further studied the contribution of interactions among significant descriptors in enhancing the activity of the compounds. It revealed that the presence of Sum((R1-SsssCHcount, R2-slogp) and Mult(R1-chi3, R3-polarizabilityAHC) are the most significantly influencing descriptors. We further compared the variation in the most and least active compounds which established that retention of the above properties is essential for imparting significant inhibitory activity to these molecules. Conclusion: The study provides site specific information wherein chemical group variation influences the inhibitory potency of TMLR amino-pyrimidine inhibitors, which can be used for designing new molecules with the desired activity.


Sign in / Sign up

Export Citation Format

Share Document